HISTORICAL GAAP P&L TREND - CONSOLIDATED ($000's)

	2019	2020	Q121	Q221	Q321	Q421	2021	Q122	Q222	Q322
Revenues:										
Revenue from products and services	108,242	141,079	43,716	61,885	62,735	73,922	242,258	70,918	84,151	89,839
Revenue from Int'l supply agreement	5,185	3,782	405	364	145	40	954	15	-	-
TOTAL REVENUE	**113,427**	**144,861**	**44,121**	**62,249**	**62,880**	**73,962**	**243,212**	**70,933**	**84,151**	**89,839**
Cost of revenue	35,833	42,360	12,263	21,184	23,266	28,737	85,450	21,717	28,675	30,323
Total gross profit	**77,594**	**102,501**	**31,858**	**41,065**	**39,614**	**45,225**	**157,762**	**49,216**	**55,476**	**59,516**
Operating expenses (GAAP):										
Research & development	15,486	18,745	5,801	7,839	9,391	8,984	32,015	9,722	10,596	12,111
Sales, general & administrative	100,077	129,156	40,426	60,659	61,494	66,692	229,271	69,471	72,668	75,954
Litigation-related	8,549	8,552	3,335	1,167	1,209	5,412	11,123	7,532	5,495	3,602
Amortization of acquired intangible assets	698	688	172	1,208	2,012	1,956	5,348	2,230	2,177	2,774
Transaction-related expenses	-	4,223	1,012	4,771	373	209	6,365	120	-	-
Restructuring expenses	60	-	158	1,173	256	110	1,697	1,370	289	45
Gain on Settlement	-	-	-	-	-	-	-	-	-	-
Total operating expenses (GAAP)	**124,870**	**161,364**	**50,904**	**76,817**	**74,735**	**83,363**	**285,819**	**90,445**	**91,225**	**94,486**
TOTAL OPERATING LOSS	**(47,276)**	**(58,863)**	**(19,046)**	**(35,752)**	**(35,121)**	**(38,138)**	**(128,057)**	**(41,229)**	**(35,749)**	**(34,970)**
Other income (expense):										
Interest and other income (expense),net	(9,865)	(12,374)	(3,827)	(2,410)	(386)	(2,048)	(8,671)	(1,486)	(1,368)	(1,900)
Loss on debt extinguishment	-	(7,612)	-	-	(7,434)	-	(7,434)	-	-	-
Gain on change in fair value of warrants	-	-	-	-	-	-	-	-	-	-
Total other income (expense), net	**(9,865)**	**(19,986)**	**(3,827)**	**(2,410)**	**(7,820)**	**(2,048)**	**(16,105)**	**(1,486)**	**(1,368)**	**(1,900)**
Income (loss) from continuing operations (GAAP)	**(57,141)**	**(78,849)**	**(22,873)**	**(38,162)**	**(42,941)**	**(40,186)**	**(144,162)**	**(42,715)**	**(37,117)**	**(36,870)**
Income tax provision	(239)	145	30	43	90	1	164	129	203	129
Net loss from continuing operations	**(56,902)**	**(78,994)**	**(22,903)**	**(38,205)**	**(43,031)**	**(40,187)**	**(144,326)**	**(42,844)**	**(37,320)**	**(36,999)**
Income (Loss) from discontinued operations	(100)	-	-	-	-	-	-	-	-	-
Net loss	**(57,002)**	**(78,994)**	**(22,903)**	**(38,205)**	**(43,031)**	**(40,187)**	**(144,326)**	**(42,844)**	**(37,320)**	**(36,999)**
Recognition of beneficial conversion feature - Series B preferred stock	-	-	-	-	-	-	-	-	-	-
Net loss attributable to common shareholders	**(57,002)**	**(78,994)**	**(22,903)**	**(38,205)**	**(43,031)**	**(40,187)**	**(144,326)**	**(42,844)**	**(37,320)**	**(36,999)**
Net loss per share	**(1.09)**	**(1.18)**	**(0.26)**	**(0.39)**	**(0.43)**	**(0.40)**	**(1.50)**	**(0.43)**	**(0.36)**	**(0.35)**
Weighted avg shares out, basic & diluted	**52,234**	**67,020**	**87,223**	**98,541**	**99,571**	**99,300**	**96,197**	**99,978**	**102,849**	**104,804**

Guidance/ Commentary

FY 2022 total revenue is expected to approximate $340M, which includes ~$46M of EOS-related revenue. The int'l supply agreement terminated Aug 2021.

Chart Area

PROFORMA GAAP P&L - EOS ($)

	Q120	Q220	Q320	Q420	2020*	Q121*	Q221*
Revenues:							
Revenue from products and services	4,096	6,685	7,389	9,021	27,191	6,865	7,945
TOTAL REVENUE	**4,096**	**6,685**	**7,389**	**9,021**	**27,191**	**6,865**	**7,945**
Cost of revenue					26,488	3,716	5,482
Total gross profit					**703**	**3,149**	**2,463**
Operating expenses (GAAP):							
Research & development					4,690	985	2,213
Sales, general & administrative					14,285	4,503	3,893
Litigation-related					-	-	-
Amortization of acquired intangible assets					7,124	1,796	1,979
Transaction-related expenses					10,298	-	-
Restructuring expenses					-	-	-
Gain on Settlement					-	-	-
Total operating expenses (GAAP)					**36,397**	**7,284**	**8,085**
TOTAL OPERATING LOSS					**(35,694)**	**(4,135)**	**(5,622)**
Other income (expense):							
Interest and other income (expense),net					300	(116)	(236)
Loss on debt extinguishment					-	-	-
Total other income (expense), net					300	**(116)**	**(236)**
Loss from continuing operations before taxes					**(35,394)**	**(4,251)**	**(5,858)**
Income tax provision (benefit)					89	18	(18)
Net loss					**(35,483)**	**(4,269)**	**(5,840)**

Data as of Q3 2022 earnings release on November 3, 2022. ATEC cautions you that statements included in this document that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of assumptions, risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that actual results will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Forward-looking statements include, but are not limited to: references to the Company's revenue and growth outlook; planned product launches, introductions, regulatory submissions or clearances; efforts to transform sales and distribution channels; the Company's ability to compel surgeon adoption; and the Company's future ability to finance its operations and sufficiency of its cash runway. Important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: the uncertainty of success in developing new products or products currently in the pipeline; the uncertainties in the Company's ability to execute upon its strategic operating plan; the uncertainties regarding the ability to successfully license or acquire new products, and the commercial success of such products; failure to achieve acceptance of the Company's products by the surgeon community; failure to obtain FDA or other regulatory clearance or approval or unexpected or prolonged delays in the process; continuation of favorable third party reimbursement; unanticipated expenses or liabilities or other adverse events affecting cash flow or the Company's ability to achieve profitability; uncertainty of additional funding; the Company's ability to compete with other products or with emerging technologies; product liability exposure; an unsuccessful outcome in any litigation; patent infringement claims; claims related to the Company's intellectual property; and the Company's ability to meet its financial obligations. A further list and description of these and other factors, risks and uncertainties can be found in the Company's most recent annual report, and any subsequent quarterly and current reports, filed with the Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law. This document contains information regarding the Company's financial results that is calculated and presented on the basis of methodologies other than in accordance with accounting principles generally accepted in the United States ("GAAP"). These non-GAAP financial measures are not measures of financial performance in accordance with GAAP and may exclude items that are significant in understanding and assessing our financial results. Therefore, these measures should not be considered in isolation or as an alternative or superior to GAAP measures. Be aware that our presentation of these measures may not be comparable to similarly-titled measures used by other companies.

NON-GAAP RECONCILIATION - CONSOLIDATED ($000's)

ADJUSTED EBITDA	2019	2020	Q121	Q221	Q321	Q421	2021	Q122	Q222	Q322
Operating loss, GAAP	(47,276)	(58,863)	(19,046)	(35,752)	(35,121)	(38,138)	(128,057)	(41,229)	(35,749)	(34,970)
Depreciation	6,775	9,186	3,409	5,068	5,311	6,544	20,332	7,085	7,506	8,010
Amortization of intangible assets	803	1,763	441	1,476	2,281	2,226	6,424	2,230	2,186	2,802
Total EBITDA	**(39,698)**	**(47,914)**	**(15,196)**	**(29,208)**	**(27,529)**	**(29,368)**	**(101,301)**	**(31,914)**	**(26,057)**	**(24,158)**
+ Stock-based compensation	10,954	17,659	4,474	11,496	10,754	9,726	36,450	10,184	9,203	11,077
+ Purchase accounting adjustments on acquisitions	-	-	-	1,763	2,577	2,083	6,423	-	437	347
+ Excess & obsolete charges	8,624	7,044	2,096	2,221	2,525	4,305	11,147	1,706	2,394	2,923
+ Contingent consideration fair value adjustment	289	-	-	-	-	-	-	-	-	-
+ Litigation-related expenses	8,549	8,552	3,335	1,167	1,209	5,412	11,123	7,532	5,495	3,602
+ Transaction-related expenses	-	4,223	1,012	4,771	373	209	6,365	120	-	-
+ Restructuring expenses	60	-	158	1,173	256	110	1,697	1,370	289	45
+ Gain on settlement	-	-	-	-	-	-	-	-	-	-
Total Adjusted EBITDA	**(11,222)**	**(10,436)**	**(4,121)**	**(6,617)**	**(9,835)**	**(7,523)**	**(28,096)**	**(11,002)**	**(8,239)**	**(6,164)**
Adjusted EBITDA as a % of Revenue	***-9.9%***	***-7.2%***	***-9.3%***	***-10.6%***	***-15.6%***	***-10.2%***	***-11.6%***	***-15.5%***	***-9.8%***	***-6.9%***

Chart Area

Adjusted EBITDA for the full year 2022 is expected to approximate ($28M).

NON-GAAP GROSS PROFIT & GM%	2019	2020	Q121	Q221	Q321	Q421	2021	Q122	Q222	Q322
Gross Profit, GAAP	77,594	102,501	31,858	41,065	39,614	45,225	157,762	49,216	55,476	59,516
+ Amortization of intangible assets	105	1,075	269	268	270	268	1,075	-	9	28
+ Stock-based compensation	146	512	95	84	310	248	737	256	449	735
+ Purchase accounting adjustments on acquisitions	-	-	-	1,763	2,577	2,083	6,423	-	437	347
+ Excess & obsolescence charges	8,624	7,044	2,096	2,221	2,525	4,305	11,147	1,706	2,394	2,923
Non-GAAP Gross Profit	**86,469**	**111,132**	**34,318**	**45,401**	**45,296**	**52,129**	**177,144**	**51,178**	**58,765**	**63,549**
Gross Margin, GAAP	**68.4%**	**70.8%**	**72.2%**	**66.0%**	**63.0%**	**61.1%**	**64.9%**	**69.4%**	**65.9%**	**66.2%**
+ Amortization of intangible assets	0.1%	0.7%	0.6%	0.4%	0.4%	0.4%	0.4%	0.0%	0.0%	0.0%
+ Stock-based compensation	0.1%	0.4%	0.2%	0.1%	0.5%	0.3%	0.3%	0.4%	0.5%	0.8%
+ Purchase accounting adjustments on acquisitions	0.0%	0.0%	0.0%	2.8%	4.1%	2.8%	2.6%	0.0%	0.5%	0.4%
+ Excess & obsolescence charges	7.6%	4.9%	4.8%	3.6%	4.0%	5.8%	4.6%	2.4%	2.8%	3.3%
Non-GAAP Gross Margin	**76.2%**	**76.7%**	**77.8%**	**72.9%**	**72.0%**	**70.5%**	**72.8%**	**72.1%**	**69.7%**	**70.7%**

NON-GAAP OPERATING EXPENSES	2019	2020	Q121	Q221	Q321	Q421	2021	Q122	Q222	Q322
Research & Development, GAAP	**15,486**	**18,745**	**5,801**	**7,839**	**9,391**	**8,984**	**32,015**	**9,722**	**10,596**	**12,111**
- Stock-based compensation in R&D	1,044	2,074	498	664	1,440	1,454	4,056	972	1,362	1,653
- Contingent consideration fair value adjustm	289	-	-	-	-	-	-	-	-	-
Non-GAAP R&D	**14,153**	**16,671**	**5,303**	**7,175**	**7,951**	**7,530**	**27,959**	**8,750**	**9,234**	**10,458**
Sales General & Administrative, GAAP	**100,077**	**129,156**	**40,426**	**60,659**	**61,494**	**66,692**	**229,271**	**69,471**	**72,668**	**75,954**
- Stock-based compensation in SG&A	9,764	15,073	3,881	10,748	9,004	8,024	31,657	8,956	7,392	8,689
- Purchase accounting adjustments on acquisitions	-	-	-	-	-	-	-	-	-	-
Non-GAAP SG&A	**90,313**	**114,083**	**36,545**	**49,911**	**52,490**	**58,668**	**197,614**	**60,515**	**65,276**	**67,265**
Other Operating Expense, GAAP	**9,307**	**13,463**	**4,677**	**8,319**	**3,850**	**7,687**	**24,533**	**11,252**	**7,961**	**6,421**
- Litigation-related expenses	8,549	8,552	3,335	1,167	1,209	5,412	11,123	7,532	5,495	3,602
- Amortization of intangible assets	698	688	172	1,208	2,012	1,956	5,348	2,230	2,177	2,774
- Transaction-related expenses	-	4,223	1,012	4,771	373	209	6,365	120	-	-
- Restructuring expenses	60	-	158	1,173	256	110	1,697	1,370	289	45
- Gain on settlement	-	-	-	-	-	-	-	-	-	-
Non-GAAP Other Operating Expense	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**
Total Non-GAAP Operating Expenses	**104,466**	**130,754**	**41,848**	**57,086**	**60,441**	**66,198**	**225,573**	**69,265**	**74,510**	**77,723**
NG Operating Expenses % of Revenue										
Research & development	12.5%	11.5%	12.0%	11.5%	12.6%	10.2%	11.5%	12.3%	11.0%	11.6%
Sales, general & administrative	79.6%	78.8%	82.8%	80.2%	83.5%	79.3%	81.3%	85.3%	77.6%	74.9%
Total NG Operating Exp % of Revenue	**92.1%**	**90.3%**	**94.8%**	**91.7%**	**96.1%**	**89.5%**	**92.8%**	**97.6%**	**88.5%**	**86.5%**

HISTORICAL NON-GAAP U.S. GP & GM	2019	2020	Q121
U. S. Gross Margin, GAAP	**77,235**	**102,449**	31,975
+ Excess & obsolescence charges	8,624	7,044	2,096
Non-GAAP U.S. Gross Margin	**85,859**	**109,493**	**34,071**

NON-GAAP RECONCILIATION - EOS ($)

ADJUSTED EBITDA	Q120	Q220	Q320	Q420	2020*	Q121*	Q221*
Operating loss, GAAP					(35,694)	(4,135)	(5,622)
Depreciation					806	194	200
Amortization of intangible assets					7,124	1,796	1,979
Total EBITDA	**-**	**-**	**-**	**-**	**(27,764)**	**(2,145)**	**(3,443)**
+ Stock-based compensation					-	-	-
+ Purchase accounting adjustments	-	-	-	-	8,600	-	-
+ Excess & obsolete charges					-	-	-
+ Contingent consideration fair value adjustment					-	-	-
+ Litigation-related expenses					-	-	-
+ Transaction-related expenses					10,298	-	-
+ Restructuring expenses					-	-	-
+ Gain on settlement					-	-	-
Total Adjusted EBITDA	**-**	**-**	**-**	**-**	**(8,866)**	**(2,145)**	**(3,443)**
Adjusted EBITDA as a % of Revenue					**-32.6%**	**-31.2%**	**-43.3%**

NON-GAAP GROSS PROFIT & GR	Q120	Q220	Q320	Q420	2020	Q121	Q221
Gross Profit, GAAP					**703**	3,149	2,463
+ Amortization of intangible assets					**-**	-	-
+ Stock-based compensation					**-**	-	-
+ Purchase accounting adjustments on acquisitions					**8,600**	-	-
+ Excess & obsolescence charges					-	-	-
Non-GAAP Gross Profit					**9,303**	**3,149**	**2,463**
Gross Margin, GAAP					**2.6%**	**45.9%**	**31.0%**
+ Amortization of intangible assets					0.0%	0.0%	0.0%
+ Stock-based compensation					0.0%	0.0%	0.0%
+ Purchase accounting adjustments on acquisitions					31.6%	0.0%	0.0%
+ Excess & obsolescence charges					0.0%	0.0%	0.0%
Non-GAAP Gross Margin					**34.2%**	**45.9%**	**31.0%**

NON-GAAP OPERATING EXPENS	Q120	Q220	Q320	Q420	2020	Q121	Q221
Research & Development, GAAP					**4,690**	**985**	**2,213**
- Stock-based compensation in R&D					-	-	-
- Contingent consideration fair value adjustment					-	-	-
Non-GAAP R&D					**4,690**	**985**	**2,213**
Sales General & Administrative, GAAP					**14,285**	**4,503**	**3,893**
- Stock-based compensation in SG&A					-	-	-
- Purchase accounting adjustments on acquisitions					-		-
Non-GAAP SG&A					**14,285**	**4,503**	**3,893**
Other Operating Expense, GAAP					**17,422**	**1,796**	**1,979**
- Litigation-related expenses					-	-	-
- Amortization of intangible assets					7,124	1,796	1,979
- Transaction-related expenses					10,298	-	-
- Restructuring expenses					-	-	-
- Gain on settlement					-	-	-
Non-GAAP Other Operating Expense					**-**	**-**	**-**
Total Non-GAAP Operating Expenses					**18,975**	**5,488**	**6,106**
Non-GAAP Operating Expenses as a % of Revenue							
Research & development					17.2%	14.3%	27.9%
Sales, general & administrative					52.5%	65.6%	49.0%
Total Non-GAAP Operating Expenses as a % of Revenue					**69.8%**	**79.9%**	**76.9%**

NON-GAAP P&L TREND - CONSOLIDATED ($000's)

	2019	2020	Q121	Q221	Q321	Q421	2021	Q122	Q222	Q322
Revenue	**113,427**	**144,861**	**44,121**	**62,249**	**62,880**	**73,962**	**243,212**	**70,933**	**84,151**	**89,839**
Non-GAAP cost of sales	26,958	33,729	9,803	16,848	17,584	21,833	66,068	19,755	25,386	26,290
Non-GAAP gross profit	**86,469**	**111,132**	**34,318**	**45,401**	**45,296**	**52,129**	**177,144**	**51,178**	**58,765**	**63,549**
Non-GAAP Gross Margin	*76.2%*	*76.7%*	*77.8%*	*72.9%*	*72.0%*	*70.5%*	*72.8%*	*72.1%*	*69.7%*	*70.7%*
Operating expenses (Non-GAAP):										
Research & development, Non-GAAP	14,153	16,671	5,303	7,175	7,951	7,530	27,959	8,750	9,234	10,458
Sales, general & administrative, Non-GAAP	90,313	114,083	36,545	49,909	52,490	58,669	197,613	60,515	65,276	67,265
Total operating expenses (Non-GAAP)	**104,466**	**130,754**	**41,848**	**57,084**	**60,441**	**66,199**	**225,572**	**69,265**	**74,510**	**77,723**
R&D as % of revenue	*12.5%*	*11.5%*	*12.0%*	*11.5%*	*12.6%*	*10.2%*	*11.5%*	*12.3%*	*11.0%*	*11.6%*
SG&A as % of revenue	*79.6%*	*78.8%*	*82.8%*	*80.2%*	*83.5%*	*79.3%*	*81.3%*	*85.3%*	*77.6%*	*74.9%*
Total OPEX as % of revenue	*92.1%*	*90.3%*	*94.8%*	*91.7%*	*96.1%*	*89.5%*	*92.7%*	*97.6%*	*88.5%*	*86.5%*
Non-GAAP operating loss	**(17,997)**	**(19,622)**	**(7,530)**	**(11,683)**	**(15,145)**	**(14,070)**	**(48,428)**	**(18,087)**	**(15,745)**	**(14,174)**
Op loss as % of revenue	*-15.9%*	*-13.5%*	*-17.1%*	*-18.8%*	*-24.1%*	*-19.0%*	*-19.9%*	*-25.5%*	*-18.7%*	*-15.8%*
Less: Depreciation	6,775	9,186	3,409	5,068	5,311	6,544	20,332	7,085	7,506	8,010
Adjusted EBITDA	**(11,222)**	**(10,436)**	**(4,121)**	**(6,615)**	**(9,834)**	**(7,526)**	**(28,096)**	**(11,002)**	**(8,239)**	**(6,164)**
Adj EBITDA as % of revenue	*-9.9%*	*-7.2%*	*-9.3%*	*-10.6%*	*-15.6%*	*-10.2%*	*-11.6%*	*-15.5%*	*-9.8%*	*-6.9%*

NON-GAAP P&L TREND - EOS ($000's)

	Q120	Q220	Q320	Q420	2020*	Q121*	Q221*
Revenue	**4,096**	**6,685**	**7,389**	**9,021**	**27,191**	**6,865**	**7,945**
Non-GAAP cost of sales					17,888	3,716	5,482
Non-GAAP gross profit					**9,303**	**3,149**	**2,463**
Non-GAAP Gross Margin					*34.2%*	*45.9%*	*31.0%*
Operating expenses (Non-GAAP):							
Research & development, Non-GAAP					4,690	985	2,213
Sales, general & administrative, Non-GAAP					14,285	4,503	3,893
Total operating expenses (Non-GAAP)					**18,975**	**5,488**	**6,106**
R&D as % of revenue					*17.2%*	*14.3%*	*27.9%*
SG&A as % of revenue					*52.5%*	*65.6%*	*49.0%*
Total OPEX as % of revenue					*69.8%*	*79.9%*	*76.9%*
Non-GAAP operating losss					**(9,672)**	**(2,339)**	**(3,643)**
Op loss as % of revenue					*-35.6%*	*-34.1%*	*-45.9%*
Less: Depreciation					806	194	200
Adjusted EBITDA					**(8,866)**	**(2,145)**	**(3,443)**
Adj EBITDA as % of revenue					*-32.6%*	*-31.2%*	*-43.3%*

**Based on combined information disclosed in the 8-K/A filed on July 23, 2021 and 10-Q filed on Aug 3, 2021.*

Chart Area

REVENUE SUPPLEMENT

	2019	2020	Q121	Q221	Q321	Q421	2021	Q122	Q222	Q322
Revenues:										
Products and services - Surgical	108,242	141,079	43,716	55,769	51,604	61,151	212,240	60,649	72,343	78,727
Products and services - Imaging	-	-	-	6,116	11,131	12,771	30,018	10,269	11,808	11,112
Revenue from products and services	108,242	141,079	43,716	61,885	62,735	73,922	242,258	70,918	84,151	89,839
Revenue from Int'l supply agreement	5,185	3,782	405	364	145	40	954	15	-	-
TOTAL REVENUE	**113,427**	**144,861**	**44,121**	**62,249**	**62,880**	**73,962**	**243,212**	**70,933**	**84,151**	**89,839**
Constant currency adjustments:										
Products and services - Surgical	-	-	-	-	-	-	-	-	-	-
Products and services - EOS	-	-	-	-	-	-	-	293	615	807
Revenue from products and services	-	-	-	-	-	-	-	293	615	807
Revenue from Int'l supply agreement	-	-	-	-	-	-	-	-	-	-
TOTAL ADJUSTMENTS	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**293**	**615**	**807**
Revenues at constant currency:										
Products and services - Surgical	108,242	141,079	43,716	55,769	51,604	61,151	212,240	60,649	72,343	78,727
Products and services - EOS	-	-	-	6,116	11,131	12,772	30,019	10,562	12,424	11,919
Revenue from products and services	108,242	141,079	43,716	61,885	62,735	73,923	242,259	71,211	84,767	90,646
Revenue from Int'l supply agreement	5,185	3,782	405	364	145	40	954	15	-	-
TOTAL REVENUE AT CONSTANT CURRENCY	**113,427**	**144,861**	**44,121**	**62,249**	**62,880**	**73,963**	**243,213**	**71,226**	**84,767**	**90,646**

YOY GROWTH %	**2019**	**2020**	**Q121**	**Q221**	**Q321**	**Q421**	**2021**	**Q122**	**Q222**	**Q322**
Products and services - Surgical	29.4%	30.3%	50.4%	93.4%	28.8%	41.8%	50.4%	38.7%	29.7%	52.6%
Products and services - Imaging									93.1%	-0.2%
Revenue from products and services	29.4%	30.3%	50.4%	114.6%	56.6%	71.4%	71.7%	62.2%	36.0%	43.2%
Revenue from Int'l supply agreement	-35.5%	-27.1%	-61.2%	-54.2%	-86.9%	-95.2%	-74.8%	-96.3%	-100.0%	-100.0%
TOTAL REVENUE	**23.7%**	**27.7%**	**46.5%**	**110.1%**	**52.8%**	**68.3%**	**67.9%**	**60.8%**	**35.2%**	**42.9%**
YOY growth % at constant currency:										
Products and services - Surgical	29.4%	30.3%	50.4%	93.4%	28.8%	41.8%	50.4%	38.7%	29.7%	52.6%
Products and services - EOS									103.1%	7.1%
Revenue from products and services	29.4%	30.3%	50.4%	114.6%	56.6%	71.4%	71.7%	62.9%	37.0%	44.5%
Revenue from Int'l supply agreement	-35.5%	-27.1%	-61.2%	-54.2%	-86.9%	-95.2%	-74.8%	-96.3%	-100.0%	-100.0%
TOTAL REVENUE GROWTH % AT CONSTANT CURRENCY	**23.7%**	**27.7%**	**46.5%**	**110.1%**	**52.8%**	**68.3%**	**67.9%**	**61.4%**	**36.2%**	**44.2%**

PRODUCT CATEGORIES PER CASE	**2019**	**2020**	**Q121**	**Q221**	**Q321**	**Q421**	**2021**	**Q122**	**Q222**	**Q322**
Historical Product Categories per Case	1.6	1.8	1.9	2.0	2.0	2.0	2.0			
Product Categories per Case (inclusive of bulk	1.7	1.9	2.0	2.1	2.1	2.1	2.1	2.1	2.2	2.3

See forward looking statement information on page 1.